Executive Changes at Vectura

On 31 March 2022, both Will Downie and Paul Fry stepped down from their respective roles as Chief Executive Officer and Chief Financial Officer at Vectura. Under their leadership, Vectura [plc] made significant progress towards its transformation, and today Vectura is recognised as, a valued partner in the pharmaceutical industry for the development of inhaled therapeutic products.

Jorge Insuasty, Chief Life Sciences Officer at PMI, paid tribute to Will and Paul and said: “Since joining Vectura, Will and Paul have developed Vectura into a leading inhaled therapeutic products company. The respect and esteem with which Vectura employees hold them is rightly high, and we thank Will and Paul for their leadership and stewardship of the company”